SUPN Q2 2023 Earnings — Supernus Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

SUPNSupernus Pharmaceuticals, Inc.

$3B

Q2 2023 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$136M-20.3% YoY

Gross Profit

$114M84.4% margin

Operating Income

-$18M-13.0% margin

Net Income

-$831,000-0.6% margin

EPS (Diluted)

$-0.02

QoQ Revenue Growth

-11.8%

Cash Flow

Operating Cash Flow

-$19M

Free Cash Flow

-$19M

Stock-Based Comp.

$6M

Balance Sheet

Total Assets

$1.3B

Total Liabilities

$373M

Stockholders' Equity

$920M

Cash & Equivalents

$25M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$136M	$170M	-20.3%
Gross Profit	$114M	$150M	-23.5%
Operating Income	-$18M	$11M	-255.0%
Net Income	-$831,000	$8M	-110.6%

Revenue Segments

Product

$128M49%

Qelbree

$31M12%

GOCOVRI

$29M11%

Oxtellar X R

$24M9%

Trokendi Xr

$19M7%

APOKYN

$18M7%

Manufactured Product, Other

$8M3%

Royalty

$7M3%